Replies to post #209826 on Biotech Values

[DewDiligence]

MNTA ‘ReadMeFirst’ updated:

2017-2018 news flow;
reasons to be optimistic;
1Q17 financial results, liquidity, and diluted share count;
transcript of 1Q17 CC;
phase-3 trial of M923 meets FDA draft guidelines for interchange FoBs;
incoming FDA commissioner (Scott Gottlieb) emphasizes interchangeable FoBs;
an interchangeable Humira FoB for US market is badly needed (chart).

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131348030